These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36346513)

  • 1. Drug characteristics derived from kinetic modeling: combined
    Naganawa M; Gallezot JD; Finnema SJ; Maguire RP; Mercier J; Nabulsi NB; Kervyn S; Henry S; Nicolas JM; Huang Y; Chen MK; Hannestad J; Klitgaard H; Stockis A; Carson RE
    EJNMMI Res; 2022 Nov; 12(1):71. PubMed ID: 36346513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of cerebral drug occupancy in humans using a single PET-scan: A [
    Marstrand-Joergensen MR; Laurell GL; Herrmann S; Nasser A; Johansen A; Lund A; Andersen TL; Knudsen GM; Pinborg LH
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3292-3304. PubMed ID: 38758370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-Human Evaluation of
    Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation and noninvasive kinetic modeling of [
    Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
    J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of [
    Goutal S; Guillermier M; Becker G; Gaudin M; Bramoullé Y; Luxen A; Lemaire C; Plenevaux A; Salmon E; Hantraye P; Barret O; Van Camp N
    EJNMMI Res; 2021 Apr; 11(1):36. PubMed ID: 33826008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain.
    Warnock GI; Aerts J; Bahri MA; Bretin F; Lemaire C; Giacomelli F; Mievis F; Mestdagh N; Buchanan T; Valade A; Mercier J; Wood M; Gillard M; Seret A; Luxen A; Salmon E; Plenevaux A
    J Nucl Med; 2014 Aug; 55(8):1336-41. PubMed ID: 24935992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and Economic Outcomes of Intravenous Brivaracetam Compared With Levetiracetam for the Treatment of Seizures in United States Hospitals.
    Beaty S; Rosenthal NA; Gayle J; Dongre P; Ricchetti-Masterson K
    Front Neurol; 2021; 12():760855. PubMed ID: 34912285
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential of [
    Puuvuori E; Rokka J; Carlsson PO; Li Z; Eriksson J; Eriksson O
    Sci Rep; 2021 Dec; 11(1):24466. PubMed ID: 34963683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
    Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M
    Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying SV2A density and drug occupancy in the human brain using [
    Koole M; van Aalst J; Devrome M; Mertens N; Serdons K; Lacroix B; Mercier J; Sciberras D; Maguire P; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):396-406. PubMed ID: 30121895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and 28-day test-retest repeatability and reproducibility of [
    Tuncel H; Boellaard R; Coomans EM; de Vries EF; Glaudemans AW; Feltes PK; García DV; Verfaillie SC; Wolters EE; Sweeney SP; Ryan JM; Ivarsson M; Lynch BA; Schober P; Scheltens P; Schuit RC; Windhorst AD; De Deyn PP; van Berckel BN; Golla SS
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.